ALL INPredictions
Last updated Nov 29, 2025
Prediction
Friedberg
← Back to hostEpisode
Friedberg @ 01:15:40Inconclusive
healthscience
Within roughly 15 years from February 2022 (by ~2037), autologous induced stem cell therapies—where a patient’s own cells are reprogrammed into stem cells and used clinically not only for bone marrow transplants but for healing multiple tissue types—will be in practical therapeutic use.
that's like, you know, 15 years out is, um, autologous induced stem cell therapy, where you actually make your own stem cells and then give yourself all sorts of therapies, not just bone marrow transplants, but you can heal lots of tissue in the body using these stem cell systems.View on YouTube
Explanation

The prediction has a ~15‑year horizon from February 2022 (i.e., until around 2037). As of the current date (November 30, 2025), only about 3.8 years have elapsed, so there is still more than a decade left for it to be proven right or wrong.

On the science side, autologous induced pluripotent stem cell (iPSC) therapies are in early clinical and preclinical stages but are not yet in broad, routine “practical therapeutic use” across multiple tissues:

  • The first autologous iPSC‑derived retinal pigment epithelium (RPE) sheet transplant for age‑related macular degeneration was done in Japan in 2014; 4‑year follow‑up showed survival of the graft without major adverse events, but this was a single‑patient research intervention, not a widely available therapy. (pmc.ncbi.nlm.nih.gov)
  • A 2021 review of autologous iPSC‑based cell therapies notes that only three single‑patient in‑human autologous iPSC transplants had been performed worldwide and that one Phase I/IIa autologous iPSC trial had been initiated in the U.S., underscoring that the field is still at an early, experimental stage. (pubmed.ncbi.nlm.nih.gov)
  • More recent commentary and news (2024–2025) describe autologous iPSC‑derived therapies as a realistic but emerging approach, with efforts to industrialize and move them through early‑phase clinical studies (e.g., cardiovascular disease applications), again indicating development rather than established, routine clinical use. (insights.bio)

At the same time, other stem‑cell and gene‑modified cell therapies (including some autologous products, though generally not iPSC‑based) have reached full regulatory approval for specific indications, showing rapid progress in the broader cell‑therapy field. (en.wikipedia.org)

Because:

  1. The forecast deadline (~2037) has not yet arrived, and
  2. Current evidence shows active development but not yet the kind of widespread, multi‑tissue, autologous iPSC therapeutic use described,

there is not enough information yet to say definitively whether the prediction will end up correct or incorrect.

Therefore, the appropriate rating today is: inconclusive (too early to tell).